Ryota Imura

Mr. Ryota Imura

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Molecules
Verified
Journal Article
Open access
PDF file
RIRyota Imura
Ryota Imura
HIHiroyuki Ida
Hiroyuki Ida
ISIchiro Sasaki
Ichiro Sasaki
NINoriko S. Ishioka
Noriko S. Ishioka
Shigeki WatanabeShigeki Watanabe
Shigeki Watanabe
(1) Background: Deferoxamine B (DFO) is the most widely used chelator for labeling of zirconium-89 (89Zr) to monoclonal antibody (mAb). Despite the remarkable developments of the clinical 89Zr-immuno-PET, chemical species and stability constants of the Zr-DFO complexes remain controversial. The aim of this study was to re-evaluate their stability constants by identifying species of Zr-DFO complexes and demonstrate that the stability constants can estimate radiochemical yield (RCY) and chelator-to-antibody ratio (CAR). (2) Methods: Zr-DFO species were determined by UV and ESI-MS spectroscopy. Stability constants and speciation of the Zr-DFO complex were redetermined by potentiometric titration. Complexation inhibition of Zr-DFO by residual impurities was investigated by competition titration. (3) Results: Unknown species, ZrHqDFO2, were successfully detected by nano-ESI-Q-MS analysis. We revealed that a dominant specie under radiolabeling condition (pH 7) was ZrHDFO, and its stability constant (logβ111) was 49.1 ± 0.3. Competition titration revealed that residual oxalate inhibits Zr-DFO complex formation. RCYs in different oxalate concentration (0.1 and 0.04 mol/L) were estimated to be 86% and >99%, which was in good agreement with reported results (87%, 97%). (4) Conclusion: This study succeeded in obtaining accurate stability constants of Zr-DFO complexes and estimating RCY and CAR from accurate stability constants established in this study.

28 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
RIRyota Imura
Ryota Imura
AOAtsuko Nakanishi Ozeki
Atsuko Nakanishi Ozeki
NSNanako Shida
Nanako Shida
MKMika Kobayashi
Mika Kobayashi
HIHiroyuki Ida
Hiroyuki Ida
YKYoshitaka Kumakura
Yoshitaka Kumakura
Introduction: Prostate-specific membrane antigen (PSMA)-targeted ligands, including PSMA-617, have been developed for theranostics of prostate cancer. 68 Ga-PSMA-617 is the de facto standard of PSMA Positron Emission Tomography (PET) for imaging in prostate cancer patients prior to radioligand therapy (RLT) with 177 Lu-PSMA-617. The dose-limiting toxicity for PSMA-RLT is damage to the kidney. PET scans using 68 Ga-PSMA-617 have to be performed within a few hours of injection due to its short half-life (68 min). However, the presence of radioactivity in urine at the PET imaging timepoint hampers the dose optimization of 177 Lu (half-life 6.6 d)-labeled PSMA-617. Thus, the long-lived positron emitter 89 Zr (half-life 3.3 d) is suited for optimizing the doses of 177 Lu-PSMA-617 because PET scans can be performed after excretion of radioactive urine. Although 89 Zr has great potential for PET imaging, its inadequate incorporation into 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), limits its applications. Here, we report the radiolabeling of PSMA-617 with 89 Zr and preliminary PET imaging studies using 89 Zr-PSMA-617. Methods: DMSO and HEPES buffer were used to label PSMA-617 with 89 Zr. The dissociation constant ( K d ) of 89 Zr-PSMA-617 was determined using a cell-binding assay. Delayed-PET scans using 89 Zr-PSMA-617 were performed at 24 h (N = 5). Results: 89 Zr-PSMA-617 was prepared with a radiochemical yield of 70 ± 9%. The K d value was 6.8 nM. In PET imaging, standardized uptake value (SUV) was highest in LNCaP tumors (SUV max = 0.98 ± 0.32), whereas it was low in kidney (SUV max = 0.18 ± 0.7). Conclusion: The preparation of 89 Zr-PSMA-617 was achieved by using the DMSO and HEPES buffer. 89 Zr-PSMA-617 visualize the PSMA positive LNCaP tumors without accumulation in bladder. Advances in knowledge and implications for patient care: The use of 89 Zr-PSMA-617 to predict the radiation doses in normal tissues lead to safe and effective RLT with 177 Lu-PSMA-617.

12 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RIRyota Imura
Ryota Imura
YKYoshitaka Kumakura
Yoshitaka Kumakura
LYLin Yan
Lin Yan
YSYuki Shimoura
Yuki Shimoura
HTHiroyuki Takahashi
Hiroyuki Takahashi
NANobuyoshi Akimitsu
Nobuyoshi Akimitsu
Currently, the DFO chelator is commonly used to conjugate monoclonal antibodies (mAbs) and 89 Zr, whereas the DOTA chelator is commonly used to conjugate mAbs and alpha- and beta-emitting metal radionuclides. However, if the degradation of [ 89 Zr]Zr-DFO-mAb is not negligible, the in vivo biodistribution of 89 Zr might not reflect that of metal radionuclides conjugated with DOTA-mAb. We hypothesized that [ 89 Zr]Zr-DOTA-mAb as a new imaging counterpart would accurately predict the biodistribution of therapeutic metal radionuclides delivered by DOTA-mAb. In this study, we prepared [ 89 Zr]Zr-DOTA-trastuzumab for the first time by a two-step reaction using click chemistry and then investigated the differences in biodistribution profiles between two chelating approaches for 89 Zr. Methods: We prepared [ 89 Zr]Zr-DOTA-trastuzumab from DOTA-tetrazine conjugates (DOTA-Tz) and transcyclooctene-trastuzumab conjugates (TCO-trastuzumab). We first radiolabeled DOTA-Tz with 89 Zr in a reaction solution of MeOH and HEPES buffer and then used a click reaction to obtain [ 89 Zr]Zr-DOTA-Tz/TCO-trastuzumab. We performed biodistribution studies and PET imaging with [ 89 Zr]Zr-DOTA-trastuzumab in a mouse model of HER2-positive ovarian cancer, SKOV3 xenograft mice at 24, 72, and 144 hours post-injection and compared these data with those of [ 89 Zr]Zr-DFO-trastuzumab. Results: TCO-trastuzumab was radiolabeled with [ 89 Zr]Zr-DOTA-Tz in the two-step reaction in good radiochemical yield (57.8 ± 17.6%). HER2-positive tumors were clearly visualized with [ 89 Zr]Zr-DOTA-trastuzumab in PET imaging studies. The temporal profile changes of 89 Zr radioactivity in SKOV3 tumors and bone marrow were sufficiently different between [ 89 Zr]Zr-DOTA-trastuzumab and [ 89 Zr]Zr-DFO-trastuzumab (P < 0.05). Conclusion: [ 89 Zr]Zr-DOTA-trastuzumab can be produced by the two-step radiolabeling reaction based on the Tz/TCO click reaction. Presumably, 89 Zr released from DFO is not negligible. In contrast, [ 89 Zr]Zr-DOTA-mAb would better predict the biodistribution of [ 177 Lu]Lu- or [ 225 Ac]Ac-DOTA-mAb than [ 89 Zr]Zr-DFO-mAb, thus avoiding the use of different chelator for 89 Zr at the expense of the click chemistry step. Graphical